Drostanolone (Masterone) is medically prescribed as an anti-estrogenic therapy for the treatment of advanced inoperable breast cancer in postmenopausal women.
It was originally manufactured under pharmaceutical production by Lilly/Syntex during the 1970s.
The drug is an injectable AAS derived from dihydrotestosterone (DHT).
It presents milder androgenicity than testosterone and higher anabolic index, similar to that of nandrolone.
Drostanolone has anti-estrogenic properties, since there is no aromatisation (conversion to estrogen) and water retention; therefore, the drug usually replaces testosterone.
It is advisable to be used during the end of a precontest preparation, when physique has low body fat percentage and looks “harder”.
Masteron is available in fast-propionate ester, thus it should be administrated every other day or so.
It can be stacked perfectly well with trenbolone and fluoxymesterone during the last two weeks before a contest.
Both drostanolone and mesterolone (injectable and per os forms DHT), can be alternative anti-estrogenic options combined with tamoxifen citrate (SERM).
This plan avoids the use of powerful aromatase inhibitors, which can become harmful to serum lipids (HDL, LDL, cholesterol) and lipoprotein ratio (HDL/LDL).
Drostanolone affects the metabolism of 5a reductase and production of DHT.
Therefore, hypertrophy of the prostate gland (BPH) or male alopecia (MPB) are more likely to occur.